文献速递糖尿病

低剂量格列齐特对2型糖尿病患者肠促胰素效应及β细胞功能的影响

The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本研究在16例HbA1c<64 mmol/mol(8.0%)、仅饮食或二甲双胍单药治疗的2型糖尿病患者中,通过配对的口服葡萄糖耐量试验和等血糖输注,评估单次20 mg格列齐特对经典肠促胰素效应和β细胞功能的影响。结果显示,格列齐特降低OGTT期间平均血糖,将经典肠促胰素效应从35.5%提高至54.99%,并增加β细胞葡萄糖敏感性和晚相肠促胰素增强。结论提示低剂量格列齐特可增强肠促胰素作用,可能有效降糖而不增加低血糖风险。

要点

  • 单次20 mg格列齐特降低OGTT平均血糖,并增强经典肠促胰素效应。
  • 格列齐特使β细胞葡萄糖敏感性提高46%,并增强晚相肠促胰素增效。
  • 低剂量格列齐特可能通过增强肠促胰素作用降糖而不引起低血糖。

核心结论

  • 低剂量格列齐特降低口服葡萄糖负荷后的血浆葡萄糖,并伴随经典肠促胰素效应的增强。
  • β细胞建模显示低血浆浓度格列齐特增强晚相胰岛素分泌,并使葡萄糖敏感性提高约50%。
  • 需进一步研究低剂量格列齐特是否通过增强肠促胰素作用有效降糖而不伴低血糖风险。

研究设计与样本

  • 在16例HbA1c<64 mmol/mol(8.0%)、接受饮食或二甲双胍单药治疗的2型糖尿病患者中,进行配对的口服葡萄糖耐量试验和等血糖输注。
  • 比较有无低剂量格列齐特时经典肠促胰素效应的差异,并进行β细胞功能建模描述胰岛素分泌与血糖浓度的关系。

主要发现

  • 单次20 mg格列齐特使OGTT期间平均血糖从12.01 ± 0.56 mmol/l降至10.82 ± 0.5 mmol/l(P = 0.0006;mean ± SEM)。
  • 经典肠促胰素效应由35.5%(下四分位27.3,上四分位61.2)增至54.99%(34.8,72.8;P = 0.049)。
  • 格列齐特使β细胞葡萄糖敏感性提高46%(对照22.61 ± 3.94,格列齐特33.11 ± 7.83;P = 0.01)。
  • 格列齐特增强晚相肠促胰素增效(对照0.92 ± 0.05,格列齐特1.285 ± 0.14;P = 0.038)。

临床怎么用

  • 低剂量格列齐特在2型糖尿病患者中可增强肠促胰素效应并改善β细胞功能,支持其降糖作用机制。
  • 该研究提示低剂量格列齐特可能有效降糖而不引起低血糖,但需进一步研究验证。

局限性

  • 研究样本量较小(16例),且为单次给药评估,长期疗效和安全性未明确。
  • 研究对象HbA1c<64 mmol/mol(8.0%),仅接受饮食或二甲双胍单药治疗,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Studies in permanent neonatal diabetes suggest that sulphonylureas lower blood glucose without causing hypoglycemia, in part by augmenting the incretin effect. This mechanism has not previously been attributed to sulphonylureas in patients with type 2 diabetes (T2DM). We therefore aimed to evaluate the impact of low-dose gliclazide on beta-cell function and incretin action in patients with T2DM. METHODS: Paired oral glucose tolerance tests and isoglycemic infusions were performed to evaluate the difference in the classical incretin effect in the presence and absence of low-dose gliclazide in 16 subjects with T2DM (hemoglobin A1c < 64 mmol/mol, 8.0%) treated with diet or metformin monotherapy. Beta-cell function modeling was undertaken to describe the relationship between insulin secretion and glucose concentration. RESULTS: A single dose of 20 mg gliclazide reduced mean glucose during the oral glucose tolerance test from 12.01 ± 0.56 to 10.82 ± 0.5mmol/l [P = 0.0006; mean ± standard error of the mean (SEM)]. The classical incretin effect was augmented by 20 mg gliclazide, from 35.5% (lower quartile 27.3, upper quartile 61.2) to 54.99% (34.8, 72.8; P = 0.049). Gliclazide increased beta-cell glucose sensitivity by 46% [control 22.61 ± 3.94, gliclazide 33.11 ± 7.83 (P = 0.01)] as well as late-phase incretin potentiation [control 0.92 ± 0.05, gliclazide 1.285 ± 0.14 (P = 0.038)]. CONCLUSIONS/INTERPRETATION: Low-dose gliclazide reduces plasma glucose in response to oral glucose load, with concomitant augmentation of the classical incretin effect. Beta-cell modeling shows that low plasma concentrations of gliclazide potentiate late-phase insulin secretion and increase glucose sensitivity by 50%. Further studies are merited to explore whether low-dose gliclazide, by enhancing incretin action, could effectively lower blood glucose without risk of hypoglycemia.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Cordiner RLM, Mari A, Tura A, et al. The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function. J Clin Endocrinol Metab. 2021. PMID: 33693776. doi:10.1210/clinem/dgab151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。